All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
The phase II M13-982 trial (NCT01889186) assessed venetoclax monotherapy in patients aged ≥18 years with relapsed/refractory (R/R) or previously untreated chronic lymphocytic leukemia (CLL) with a 17p deletion (del[17p]).1 The study design and primary results have previously been reported by the Lymphoma Hub. Briefly, venetoclax was associated with an overall response rate (ORR) of 77% and was well tolerated.1 Here, we summarize the 6-year follow-up and subgroup analyses from the M13-982 trial, published by Stilgenbauer, et al.1 in Blood Advances.
Table 1. Response rates in the M13-982 trial*
Response rate, % |
Venetoclax monotherapy |
---|---|
Overall response rate |
77 |
Complete remission |
21 |
Complete remission with incomplete hematological recovery |
3 |
Partial remission |
49 |
Nodular partial remission |
4 |
Stable disease |
19 |
Progressive disease |
2 |
Not evaluable |
2 |
*Data from Stilgenbauer et al.1 |
Figure 1. Long-term survival outcomes in M13-982 trial*
CR, complete remission; CRi, CR with incomplete hematological recovery; nPR, nodular partial remission; NR, not reached; OS, overall survival; PFS, progression-free survival; PR, partial remission.
*Data from Stilgenbauer et al.1
†Response at Week 36 (±4 weeks)
Figure 2. Median PFS from month 24 by MRD status in the M13-982 and MURANO trials*
MRD, measurable residual disease; NR, not reached; PFS, progression-free survival.
*Data from Stilgenbauer et al.1
†MRD status was classified as undetectable (<10−4), low MRD positive (MRD+, 10−4 to 10–2), and high MRD+ (>10−2).
Key learnings |
|
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox